Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Rhea-AI Summary

Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company focusing on developing small molecules to restore neuronal health and slow neurodegeneration. The company announced its participation in the Sidoti December Small Cap Conference to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development for neurodegenerative diseases, including Alzheimer’s disease.

Positive

• The company is focused on developing small molecules to address neurodegenerative diseases, which is a high-demand area in the pharmaceutical industry.

Negative

• None.

Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s disease

BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti December Small Cap Conference, taking place virtually from December 6-7, 2023. Details are as follows:

Sidoti December Small Cap Conference
Format: Company Presentation
Date and Time: Wednesday, December 6, 2023, from 12:15 pm - 12:45 pm EST
Location: Virtual

A live webcast of the presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay will be available for at least 30 days following the event.

Athira Pharma will also host virtual one-on-one meetings with investors on Wednesday, December 6 and Thursday, December 7. To register for the conference and schedule a one-on-one meeting, please visit
https://sidoti.com/events.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological disease by advancing its pipeline of therapeutic candidates targeting the HGF neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on X, formerly known as Twitter, and Instagram.

Investor & Media Contact:

Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

FAQ

What is Athira Pharma, Inc. (NASDAQ: ATHA) focused on developing?

Athira Pharma, Inc. (NASDAQ: ATHA) is focused on developing small molecules to restore neuronal health and slow neurodegeneration.

What is the Sidoti December Small Cap Conference?

The Sidoti December Small Cap Conference is an event where Athira Pharma, Inc. will highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development for neurodegenerative diseases.

Where can I access the live webcast of the presentation?

The live webcast of the presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor.

How can I schedule a one-on-one meeting with Athira Pharma, Inc.?

To register for the conference and schedule a one-on-one meeting, please visit https://sidoti.com/events.